Does SOTORASIB Cause Immune-mediated enterocolitis? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Immune-mediated enterocolitis have been filed in association with SOTORASIB (LUMAKRAS). This represents 0.2% of all adverse event reports for SOTORASIB.
5
Reports of Immune-mediated enterocolitis with SOTORASIB
0.2%
of all SOTORASIB reports
2
Deaths
0
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From SOTORASIB?
Of the 5 reports, 2 (40.0%) resulted in death.
Is Immune-mediated enterocolitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SOTORASIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does SOTORASIB Cause?
Non-small cell lung cancer (483)
Death (319)
Disease progression (314)
Diarrhoea (284)
Off label use (193)
Nausea (98)
Non-small cell lung cancer metastatic (93)
Hepatotoxicity (91)
Fatigue (87)
Hepatic function abnormal (80)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
Which SOTORASIB Alternatives Have Lower Immune-mediated enterocolitis Risk?
SOTORASIB vs SOTROVIMAB
SOTORASIB vs SOVALDI
SOTORASIB vs SOYBEAN OIL
SOTORASIB vs SPARSENTAN
SOTORASIB vs SPARTALIZUMAB